SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 657.80+1.6%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotechwantabe who wrote (3111)10/2/2020 1:11:25 PM
From: CuttingEdge Bio  Read Replies (2) of 3557
 
Having a fancy seronegativity diagnostic is a cool idea and all, but this is a double standard we don't apply to most other treatments. All meds work on only a subset of patients. It is nice when we can select for those MORE likely to benefit, but we don't set as a bar that you cannot treat a population if X% won't benefit, when you don't know who is in the X% group and who isn't. In my view if this shows benefits in hospitalized and it shows benefits in prophylaxis, it will be given as widely as it can be practically speaking and there won't be a 'seropositive/seronegative' litmus test even if all the benefit is driven by that subgroup. If eventually that litmus test can be developed, then it would certainly be deployed. But it wouldn't be a deal breaker for initial use.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News